瑞他鲁肽作为单分子GIP/GLP-1/胰高血糖素受体三激动剂：分子设计、药物开发及新出现的3期证据的关键解读。
摘要
瑞他鲁肽（LY3437943）是一种处于研究阶段、每周给药一次的脂化39氨基酸残基多肽，可激活葡萄糖依赖性胰岛素释放肽、胰高血糖素样肽-1及胰高血糖素受体。其分子设计将肠促胰岛素活性与胰高血糖素受体结合相结合，同时维持血糖有效性。本关键叙述性综述考察了截至2026年9月11日的分子工程、药代动力学、剂量递增、药物开发及临床证据。…
正文 待译
Retatrutide (LY3437943) is an investigational, once-weekly, lipidated 39-residue peptide that activates the glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon receptors. Its molecular design combines incretin activity with glucagon receptor engagement while maintaining glycaemic efficacy. This critical narrative review examines molecular engineering, pharmacokinetics, dose escalation, pharmaceutical development, and clinical evidence available through 11 September 2026. Five phase 3 trials have reported positive primary outcomes, but only TRANSCEND-T2D-1 has a full peer-reviewed report; the obesity trials are currently available as sponsor topline disclosures. In those disclosures, efficacy-estimand mean weight reductions of 28.3% at 80 weeks (TRIUMPH-1) and 28.7% at 68 weeks (TRIUMPH-4) were reported, with a TRIUMPH-1 treatment-regimen estimate of 25.0%; these values remain provisional pending full published trial reports. The peer-reviewed TRANSCEND-T2D-1 report supports glycaemic efficacy in early type 2 diabetes. Interpretation requires attention to estimands, population differences, treatment discontinuation and selection into trial extensions. Gastrointestinal adverse events, dysaesthesia, heart-rate changes and the functional consequences of lean-mass loss require further evaluation. Pharmaceutical priorities include scalable synthesis, impurity and potency control, formulation stability, immunogenicity and reliable dose delivery. Retatrutide provides a clinically advanced example of unimolecular poly-agonism, but comparative effectiveness, long-term outcomes and regulatory review remain essential to defining its therapeutic role.
English
Retatrutide (LY3437943) is an investigational, once-weekly, lipidated 39-residue peptide that activates the glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon receptors. Its molecular design combines incretin activity with glucagon receptor engagement while maintaining glycaemic efficacy. This critical narrative review examines molecular engineering, pharmacokinetics, dose escalation, pharmaceutical development, and clinical evidence available through 11 September 2026.…